Cart is empty Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse with many different drivers. A longtime goal for scientists in this field is finding a single drug that can treat all types of AML. A team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) scientists are closer than ever to this goal with their discovery of how a certain protein in the cell nucleus, paraspeckle component 1 (PSPC1), contributes to AML progression.
Leave A Comment